KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management

Semin Nephrol. 2015 Nov;35(6):582-589.e17. doi: 10.1016/j.semnephrol.2015.10.009.
No abstract available

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antidiuretic Hormone Receptor Antagonists / therapeutic use
  • Antihypertensive Agents / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Mechanistic Target of Rapamycin Complex 1
  • Multiprotein Complexes / antagonists & inhibitors
  • Polycystic Kidney, Autosomal Dominant / drug therapy*
  • Polycystic Kidney, Autosomal Dominant / physiopathology
  • Somatostatin / analogs & derivatives
  • TOR Serine-Threonine Kinases / antagonists & inhibitors

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antidiuretic Hormone Receptor Antagonists
  • Antihypertensive Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Multiprotein Complexes
  • Somatostatin
  • TOR Serine-Threonine Kinases
  • Mechanistic Target of Rapamycin Complex 1